Details of the Drug Combination

General Information of Drug Combination (ID: DCVQF0K)

Drug Combination Name
Galantamine Kanamycin
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Galantamine   DMEO794 Kanamycin   DM2DMPO
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 50.62
Bliss Independence Score: 50.62
Loewe Additivity Score: 64.61
LHighest Single Agent (HSA) Score: 64.61

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Galantamine
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Approved [2]
Traumatic brain injury NA07.Z Approved [3]
Galantamine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Acetylcholinesterase (AChE) TT1RS9F ACES_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Galantamine Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Galantamine Interacts with 5 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cholinesterase (BCHE) OTOH3WQ9 CHLE_HUMAN Decreases Activity [8]
Cocaine esterase (CES2) OTC647SQ EST2_HUMAN Decreases Activity [9]
Neuronal acetylcholine receptor subunit beta-2 (CHRNB2) OTNAT2M5 ACHB2_HUMAN Affects Binding [10]
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Decreases Activity [11]
Neuronal acetylcholine receptor subunit alpha-4 (CHRNA4) OT1H0ZXC ACHA4_HUMAN Affects Binding [10]
------------------------------------------------------------------------------------
Indication(s) of Kanamycin
Disease Entry ICD 11 Status REF
Bacteremia 1A73 Approved [4]
Bacterial infection 1A00-1C4Z Approved [5]
Cholangitis N.A. Approved [4]
Urinary tract infection GC08 Approved [4]
Kanamycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) TTQ8KVI F4NA87_STAAU Binder [12]
------------------------------------------------------------------------------------
Kanamycin Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Aminoglycoside O-phosphotransferase (aphA6) DEWPAJD KKA6_ACIBA Metabolism [13]
Aminoglycoside phosphotransferase (aph-Ib) DE5WGIM A0A075C7U3_CAMJU Metabolism [14]
Kanamycin/gentamycin-resistance enzyme (aacA) DECXWN8 J3S7E2_CAMCO Metabolism [14]
Endoglucanase Y (EGY) DE2M583 A0A256VAC0_LACRE Metabolism [15]
Endoglucanase Y (EGY) DE2AZTG A0A256VAC0_LACRE Metabolism [15]
------------------------------------------------------------------------------------
Kanamycin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
T-lymphocyte activation antigen CD86 (CD86) OTJCSBPC CD86_HUMAN Increases Expression [16]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6693).
3 Galantamine FDA Label
4 Kanamycin FDA Label
5 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
6 [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
7 Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-92.
8 Lichens of parmelioid clade as promising multitarget neuroprotective agents. Chem Res Toxicol. 2019 Jun 17;32(6):1165-1177.
9 Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. Chem Biol Interact. 2013 Mar 25;203(1):226-30.
10 Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol. 2005 Feb 21;509(2-3):97-108. doi: 10.1016/j.ejphar.2004.12.037.
11 Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung. 2003;54(2):183-9. doi: 10.1556/ABiol.54.2003.2.7.
12 SsrA-mediated protein tagging in the presence of miscoding drugs and its physiological role in Escherichia coli. Genes Cells. 2002 Jul;7(7):629-38.
13 Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
14 Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
15 Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
16 A plasmacytoid dendritic cell (CD123+/CD11c-) based assay system to predict contact allergenicity of chemicals. Toxicology. 2009 Oct 1;264(1-2):1-9. doi: 10.1016/j.tox.2009.07.021. Epub 2009 Aug 7.